On September 4, 2019 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, reported that it will feature a clinical poster presentation at the National Organization for Rare Disorders’ (NORD) Rare Disease and Orphan Products Breakthrough Summit taking place October 21-22, 2019 in Washington, D.C. at the Marriott Wardman Park (Press release, Bexion, SEP 4, 2019, View Source [SID1234539354]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NORD Annual Meeting
The NORD Annual Meeting brings together approximately 1000 multi-stakeholders in the rare disease community including Senior FDA officials, advocacy/patient groups, bio/pharma and solution services professionals.

First-in-human, First-in-class
Bexion’s poster is entitled, "First-in-human, First-in-class Phase 1 Study of BXQ-350 for Solid Tumors and Gliomas," and includes updated clinical information from the original poster presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in June, 2018.

Strong Safety and Tolerability
"This Phase 1 study of BXQ-350 demonstrated a strong safety and tolerability profile for a first-in-class, novel approach to treating brain and solid tumors," said Ray Takigiku, CEO and President of Bexion. "We are also highly encouraged by the evidence of possible clinical activity in some of our patients and are excited to explore the potential of this compound in future clinical trials."